CRISPR Therapeutics AG Quarterly General and Administrative Expense in USD from Q3 2015 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary: CRISPR Therapeutics AG quarterly/annual General and Administrative Expense history and growth rate from Q3 2015 to Q3 2024.
CRISPR Therapeutics AG General and Administrative Expense for the quarter ending September 30, 2024 was $17.4M, a 4.77% decline year-over-year.
CRISPR Therapeutics AG General and Administrative Expense for the twelve months ending September 30, 2024 was $71.3M, a 11.8% decline year-over-year.
CRISPR Therapeutics AG annual General and Administrative Expense for 2023 was $76.2M, a 25.7% decline from 2022.
CRISPR Therapeutics AG annual General and Administrative Expense for 2022 was $102M, a 2.78% increase from 2021.
CRISPR Therapeutics AG annual General and Administrative Expense for 2021 was $99.7M, a 16.3% increase from 2020.

General and Administrative Expense, Trailing 12 Months (USD)

General and Administrative Expense, Quarterly (USD)

General and Administrative Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	$71.3M	$17.4M	-$872K	-4.77%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-05
Q2 2024	$72.2M	$19.5M	+$449K	+2.36%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-05
Q1 2024	$71.8M	$18M	-$4.41M	-19.7%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-08
Q4 2023	$76.2M	$16.5M	-$4.69M	-22.2%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-21
Q3 2023	$80.9M	$18.3M	-$8.71M	-32.3%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-05
Q2 2023	$89.6M	$19M	-$7.24M	-27.6%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-05
Q1 2023	$96.8M	$22.4M	-$5.66M	-20.2%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-08
Q4 2022	$102M	$21.2M	-$1.49M	-6.57%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-21
Q3 2022	$104M	$27M	+$3.29M	+13.9%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-06
Q2 2022	$101M	$26.3M	-$2.53M	-8.79%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-07
Q1 2022	$103M	$28M	+$3.5M	+14.3%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	$99.7M	$22.7M	-$647K	-2.78%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-21
Q3 2021	$100M	$23.7M	+$2.17M	+10.1%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-01
Q2 2021	$98.2M	$28.8M	+$7.45M	+34.9%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-08
Q1 2021	$90.7M	$24.5M	+$4.97M	+25.4%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-09
Q4 2020	$85.7M	$23.3M	+$6.03M	+34.9%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-21
Q3 2020	$79.7M	$21.5M	+$6.02M	+38.8%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-03
Q2 2020	$73.7M	$21.4M	+$5.59M	+35.4%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-29
Q1 2020	$68.1M	$19.6M	+$4.62M	+31%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-27
Q4 2019	$63.5M	$17.3M	+$730K	+4.41%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-15
Q3 2019	$62.8M	$15.5M	+$5.34M	+52.5%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-10-28
Q2 2019	$57.4M	$15.8M	+$3.03M	+23.8%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-07-27
Q1 2019	$54.4M	$14.9M	+$6.09M	+69%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-04-28
Q4 2018	$48.3M	$16.5M	+$5.22M	+46.1%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-16
Q3 2018	$43.1M	$10.2M	+$2.06M	+25.4%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-10-28
Q2 2018	$41M	$12.7M	+$4.97M	+64%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-07-29
Q1 2018	$36M	$8.84M	+$194K	+2.25%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-04-29
Q4 2017	$35.8M	$11.3M	-$759K	-6.28%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-12
Q3 2017	$36.6M	$8.11M	+$4.01M	+97.5%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-07
Q2 2017	$32.6M	$7.77M	-$983K	-11.2%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-07
Q1 2017	$33.6M	$8.64M	+$2.53M	+41.3%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-08
Q4 2016	$31.1M	$12.1M			Oct 1, 2016	Dec 31, 2016	10-K	2019-02-25
Q3 2016		$4.11M	+$1.65M	+67.4%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016		$8.75M			Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-10
Q1 2016		$6.12M			Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-11
Q3 2015		$2.45M			Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-22

* An asterisk sign (*) next to the value indicates that the value is likely invalid.